Dark

Check out our API

ETNB
89bio, Inc. Common Stock
stock NASDAQ

Inactive

Oct 29, 2025

14.84USD0.000%(0.00)55,645,393

Pre-market

0.00USD-100.000%(-14.84)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 25, 2022

07:46AM EST The Daily Biotech Pulse: Pfizer-BioNTech Starts Omicron-Specific Vaccine Study, J&J Misses On Topline, Sierra Oncology Reports Positive Data Benzinga

07:11AM EST 89bio's NASH Candidate Shows Improvement In Disease Severity, Cardiovascular Health Benzinga

Jan 24, 2022

04:12PM EST 89bio Reports Topline Results From An Expansion Cohort Of The Phase 1b/2a Trial Of Pegozafermin For The Treatment Of NASH Benzinga

04:05PM EST 89bio Reports Positive Topline Results from an Expansion Cohort of GlobeNewswire Inc

Dec 20, 2021

11:58AM EST Benzinga's Top Ratings Upgrades, Downgrades For December 20, 2021 Benzinga

06:24AM EST HC Wainwright & Co. Initiates Coverage On 89bio with Buy Rating, Announces Price Target of $46 Benzinga

Nov 14, 2021

06:30PM EST New sub-analysis presented at The Liver Meeting 2021 shows treatment with BIO89-100 reduced spleen volume by an average of 11.8% in NASH patients GlobeNewswire Inc

Nov 11, 2021

04:26PM EST 89bio Q3 EPS $(1.41) Down From $(0.86) YoY Benzinga

04:06PM EST 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today reported its financial results for the quarter ended September 30, 2021. GlobeNewswire Inc

Nov 3, 2021

08:00AM EDT 89bio Announces Appointment of Kathy LaPorte to its Board of Directors GlobeNewswire Inc

Oct 26, 2021

07:14AM EDT Cantor Fitzgerald Assumes 89bio at Overweight, Price Target of $49 Benzinga

Oct 25, 2021

04:10PM EDT 89bio Highlights Presentation Of New Sub-Analysis From Phase 1b/2a NASH Study Of BIO89-100 At American Association for the Study of Liver Diseases Nov. 14 Benzinga

04:05PM EDT 89bio to Present New Sub-Analysis from Phase 1b/2a NASH Study of GlobeNewswire Inc

Sep 21, 2021

08:00AM EDT 89bio to Participate in the Cantor Global Healthcare Conference GlobeNewswire Inc

Sep 8, 2021

04:15PM EDT 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Companys Management will participate in the H.C. Wainwright 23rd Annual Global Investment Conference to be held September 13-15, 2021. GlobeNewswire Inc

Aug 13, 2021

09:21AM EDT RBC Capital Maintains Outperform on 89bio, Lowers Price Target to $46 Benzinga

08:54AM EDT Raymond James Maintains Outperform on 89bio, Lowers Price Target to $33 Benzinga

Aug 12, 2021

04:31PM EDT 89bio Q2 EPS $(1.03) Down From $(0.85) YoY Benzinga

04:05PM EDT - Initiated Phase 2b ENLIVEN trial in NASH patients -- Completed enrollment in NASH histology cohort with topline data expected by year-end 2021 - GlobeNewswire Inc

Aug 2, 2021

08:34AM EDT 89bio Says Completed Target Enrollment In Histology Cohort To Evaluate BIO89-100 For Treatment Of NASH Benzinga

08:30AM EDT 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that it has completed target enrollment of 20 patients in the paired-biopsy, open-label histology cohort in biopsy-confirmed fibrosis stage F2 F3 NASH patients. GlobeNewswire Inc

Jul 30, 2021

07:54AM EDT The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs Benzinga

Jul 29, 2021

08:18AM EDT The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs Benzinga

Jul 28, 2021

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

Jul 16, 2021

07:37AM EDT The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study Benzinga

Jul 15, 2021

08:08AM EDT The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs Benzinga

Jul 9, 2021

07:36AM EDT The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO Benzinga

Jul 8, 2021

07:45AM EDT The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test Benzinga

Jul 7, 2021

07:41AM EDT The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend Benzinga

Jun 16, 2021

08:00AM EDT 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Companys Management will participate in the following upcoming investor conferences in June: GlobeNewswire Inc

Jun 10, 2021

08:30AM EDT 89bio Initiates Phase 2b ENLIVEN Trial of BIO89-100 for the GlobeNewswire Inc

May 29, 2021

01:12PM EDT Notable Insider Buys Of The Last Week: Bumble, Coty, Peloton Interactive, More Benzinga

May 26, 2021

07:33AM EDT The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing Benzinga

May 25, 2021

02:49PM EDT Mid-Afternoon Market Update: Dycom Industries Drops Following Q1 Results; The Joint Corp Shares Slide Benzinga

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2021 Benzinga

08:01AM EDT 10 Biggest Price Target Changes For Tuesday Benzinga

06:59AM EDT Raymond James Downgrades 89bio to Outperform, Lowers Price Target to $35 Benzinga

May 12, 2021

04:35PM EDT 89bio Q1 EPS $(0.74) Up From $(0.76) YoY Benzinga

04:05PM EDT 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today reported its financial results for the quarter ended March 31, 2021. GlobeNewswire Inc

May 5, 2021

08:00AM EDT 89bio to Present at Upcoming Investor Conferences GlobeNewswire Inc

Apr 21, 2021

01:59PM EDT Benzinga's Top Ratings Upgrades, Downgrades For April 21, 2021 Benzinga

07:46AM EDT Cantor Fitzgerald Initiates Coverage On 89bio with Overweight Rating, Announces Price Target of $58 Benzinga

Apr 5, 2021

08:03AM EDT 89boi Receives Written Guidance From the FDA Related to Trial Design and Agreement to use Liquid Formulation for its Phase 2b Trial in NASH Benzinga

08:00AM EDT - Received written guidance from FDA related to trial design and agreement to use liquid formulation -- ENLIVEN trial to initiate as planned in 2Q21 - GlobeNewswire Inc

Mar 24, 2021

04:14PM EDT 89bio Q4 EPS $(0.63) Up From $(2.58) YoY Benzinga

04:05PM EDT 89bio Reports Fourth Quarter and Full Year 2020 Financial Results GlobeNewswire Inc

Mar 23, 2021

05:37AM EDT SVB Leerink Maintains Outperform on 89bio, Raises Price Target to $62 Benzinga

Mar 22, 2021

01:16PM EDT 89bio's NASH Candidate Shows Clinically Meaningful Outcomes At ENDO Conference Benzinga

Mar 20, 2021

11:35AM EDT 89bio Presents Additional Analysis Of Phase 1b/2a NASH Study At Annual ENDO 2021 Conference RTTNews

11:00AM EDT 89bio Presents Additional Analysis of Phase 1b/2a NASH Study at GlobeNewswire Inc

Mar 11, 2021

08:00AM EST 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Companys Management will present at the Oppenheimer 31st Annual Healthcare Conference, a virtual event, on Wednesday, March 17, 2021 at 1:10 p.m. ET. GlobeNewswire Inc

Mar 3, 2021

08:00AM EST 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Companys Management will participate in the virtual H.C. Wainwright Global Life Sciences Conference to be held March 9-10, 2021. GlobeNewswire Inc

Feb 24, 2021

08:00AM EST 89bio to Present at the 42nd Annual Raymond James Institutional GlobeNewswire Inc

Feb 18, 2021

08:00AM EST 89bio to Present at the SVB Leerink GlobeNewswire Inc

Jan 5, 2021

08:17AM EST 89bio Reports Topline Data From BIO89-100's Phase 2 SHTG Trial Expected In Second Half Of 2021; Phase 2b NASH Trial Expected To Initiate In Fist Half 2021 Benzinga

08:00AM EST -Phase 2b NASH trial as part of a potential Phase 2b/3 program expected to initiate in 1H21- GlobeNewswire Inc

Jan 4, 2021

08:00AM EST 89bio to Participate in the H.C. Wainwright BioConnect 2021 Conference GlobeNewswire Inc

Nov 24, 2020

08:00AM EST 89bio To Participate in the Piper Sandler 32nd Annual Virtual GlobeNewswire Inc

Nov 13, 2020

08:08AM EST 89bio Reports Presentation Of Updated Clinical Data From Phase 1b/2a Study Of BIO89-100 In NASH At American Association for the Study of Liver Diseases Meeting Benzinga

08:00AM EST Data demonstrated compelling efficacy profile and favorable tolerability with weekly and every two-week dosing GlobeNewswire Inc

07:40AM EST The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations Benzinga

Nov 11, 2020

04:15AM EST SVB Leerink Maintains Outperform on 89bio, Raises Price Target to $56 Benzinga

Nov 10, 2020

04:11PM EST 89bio Q3 EPS $(0.86) Misses $(0.84) Estimate Benzinga

04:02PM EST Updated clinical data from BIO89-100s Phase 1b/2a NASH trial to be presented as a late-breaking poster at upcoming AASLD Liver Meeting GlobeNewswire Inc

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Nov 2, 2020

08:10AM EST 89bio To Present Data From Phase 1b/2a Study Of BIO89-100 In NASH At AASLD's The Liver Meeting 2020 Benzinga

08:00AM EST 89bio To Present Data From Phase 1b/2a Study of BIO89-100 In NASH GlobeNewswire Inc

Oct 19, 2020

10:00AM EDT Benzinga's Top Upgrades, Downgrades For October 19, 2020 Benzinga

07:18AM EDT Raymond James Initiates Coverage On 89bio with Strong Buy Rating, Announces Price Target of $65 Benzinga

Sep 28, 2020

05:18PM EDT 89bio to Present at Upcoming Investor Conference GlobeNewswire Inc

Sep 25, 2020

07:15AM EDT B of A Securities Upgrades 89bio to Buy, Announces $43 Price Target Benzinga

Sep 23, 2020

07:00AM EDT - Longitude Venture Partners IV will build on the Firms commitment to improve clinical outcomes, enhance patient quality of life, and drive efficiency in healthcare delivery - GlobeNewswire Inc

Sep 16, 2020

08:52PM EDT 89bio Announces Pricing of Upsized Public Offering of Common Stock GlobeNewswire Inc

Sep 15, 2020

09:41AM EDT 89bio shares are trading higher after multiple firms maintained their bullish rating on the stock. Benzinga

08:20AM EDT Chardan Capital Maintains Buy on 89bio, Raises Price Target to $95 Benzinga

08:19AM EDT BTIG Maintains Buy on 89bio, Raises Price Target to $58 Benzinga

Sep 14, 2020

05:22PM EDT 89bio Reports 3M Share Common Stock Offering Benzinga

05:21PM EDT 89bio Announces Proposed Public Offering of Common Stock GlobeNewswire Inc

07:06AM EDT 89bio Announces Positive Topline Results from its Phase 1b/2a Trial of BIO89-100 in NASH; All Dose Groups Achieved Statistically Significant Reductions In Liver Fat, With Relative Reductions Of Up To 60% Versus Baseline And Up To 70% Versus Placebo Benzinga

07:01AM EDT All dose groups achieved statistically significant reductions in liver fat, with relative reductions of up to 60% versus baseline and up to 70% versus placebo GlobeNewswire Inc

Sep 13, 2020

08:32PM EDT 89bio to Announce Topline Results from Phase 1b/2a Study of BIO89-100 in NASH on Monday, September 14, 2020 Benzinga

07:54PM EDT 89bio, Inc. (Nasdaq: ETNB) today announced that the company plans to share topline safety, tolerability and efficacy data from its Phase 1b/2a study of BIO89-100 in NASH in a pre-market press release and webcast to be held on Monday, September 14, 2020. GlobeNewswire Inc

Sep 3, 2020

08:30AM EDT 89bio Initiates Phase 2 Trial Of BIO89-100 On Patients With Severe Hypertriglyceridemia Benzinga

08:30AM EDT 89bio Initiates Phase 2 Trial of BIO89-100 in Patients with Severe GlobeNewswire Inc

Aug 14, 2020

05:18AM EDT Chardan Capital Maintains Buy on 89bio, Raises Price Target to $59 Benzinga

Aug 13, 2020

04:21PM EDT 89bio Q2 EPS $0.85 Benzinga

04:06PM EDT - Topline results from BIO89-100s Phase 1b/2a NASH trial are expected in Late Q3 to Early Q4 - GlobeNewswire Inc

Aug 3, 2020

04:06PM EDT 89bio to Present at Upcoming Investor Conferences GlobeNewswire Inc

Jul 31, 2020

01:23PM EDT Piper Sandler Initiates Coverage On 89bio with Overweight Rating, Announces Price Target of $54 Benzinga

Jul 13, 2020

10:18AM EDT 89bio Announces Closing of Upsized Public Offering of Common Stock GlobeNewswire Inc

Share